BR112015024625A2 - composição de galacto-oligossacarídeo para o uso na prevenção ou tratamento de disfunção cognitiva e transtornos emocionais em doenças neuropsiquiátricas ou envelhecimento - Google Patents

composição de galacto-oligossacarídeo para o uso na prevenção ou tratamento de disfunção cognitiva e transtornos emocionais em doenças neuropsiquiátricas ou envelhecimento

Info

Publication number
BR112015024625A2
BR112015024625A2 BR112015024625A BR112015024625A BR112015024625A2 BR 112015024625 A2 BR112015024625 A2 BR 112015024625A2 BR 112015024625 A BR112015024625 A BR 112015024625A BR 112015024625 A BR112015024625 A BR 112015024625A BR 112015024625 A2 BR112015024625 A2 BR 112015024625A2
Authority
BR
Brazil
Prior art keywords
disorders
aging
prevention
treatment
cognitive dysfunction
Prior art date
Application number
BR112015024625A
Other languages
English (en)
Inventor
Tzortzis Georgios
Original Assignee
Clasado Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clasado Inc filed Critical Clasado Inc
Publication of BR112015024625A2 publication Critical patent/BR112015024625A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

resumo “composição de galacto-oligossacarídeo para o uso na prevenção ou tratamento de disfunção cognitiva e transtornos emocionais em doenças neuropsiquiátricas ou envelhecimento” uma composição de galacto-oligossacarídeo compreendendo uma mistura de dissacarídeos, trissacarídeos, um tetrassacarídeo e um pentassacarídeo para o uso na prevenção ou tratamento de disfunção cognitiva e/ou transtornos emocio-nais em doença neuropsiquiátrica ou envelhecimento.
BR112015024625A 2013-03-28 2014-03-17 composição de galacto-oligossacarídeo para o uso na prevenção ou tratamento de disfunção cognitiva e transtornos emocionais em doenças neuropsiquiátricas ou envelhecimento BR112015024625A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1305708.8A GB201305708D0 (en) 2013-03-28 2013-03-28 Novel use
PCT/GB2014/050829 WO2014155056A1 (en) 2013-03-28 2014-03-17 A galactooligosaccharide composition for use in preventing or treating cognitive dysfunction and emotional disturbances in neuropsychiatry illnesses or ageing

Publications (1)

Publication Number Publication Date
BR112015024625A2 true BR112015024625A2 (pt) 2017-07-18

Family

ID=48444941

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015024625A BR112015024625A2 (pt) 2013-03-28 2014-03-17 composição de galacto-oligossacarídeo para o uso na prevenção ou tratamento de disfunção cognitiva e transtornos emocionais em doenças neuropsiquiátricas ou envelhecimento

Country Status (19)

Country Link
US (2) US11241449B2 (pt)
EP (1) EP2978432B1 (pt)
JP (1) JP6309612B2 (pt)
KR (2) KR20210038701A (pt)
CN (1) CN105073120A (pt)
AR (1) AR095738A1 (pt)
AU (1) AU2014242798B2 (pt)
BR (1) BR112015024625A2 (pt)
CA (1) CA2908230C (pt)
ES (1) ES2722852T3 (pt)
GB (2) GB201305708D0 (pt)
HK (1) HK1204451A1 (pt)
IL (1) IL241844B (pt)
MX (1) MX2015013699A (pt)
MY (1) MY175533A (pt)
RU (1) RU2663696C2 (pt)
SG (2) SG11201507668UA (pt)
TW (1) TWI507198B (pt)
WO (1) WO2014155056A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2492559B (en) * 2011-07-05 2018-07-25 Clasado Inc Composition and method for preventing or reducing the risk of developing a syndrome
EP2886140A1 (en) * 2013-12-17 2015-06-24 University of Limerick An apparatus for the extracorporeal treatment of blood
WO2016029113A1 (en) * 2014-08-22 2016-02-25 Abbott Laboratories Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
EP3969009A1 (en) * 2019-05-15 2022-03-23 N.V. Nutricia Beta-1,3'-galactosyllactose for the treatment of gut barrier function diseases
CN115089596A (zh) * 2022-06-20 2022-09-23 自然资源部第三海洋研究所 新琼寡糖用于制备治疗抑郁症产品的新用途
GB2623335A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
US20040265279A1 (en) * 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
ES2284028T5 (es) * 2003-06-30 2014-12-04 Clasado Inc. Nueva composición de galactooligosacárido y la preparación de la misma
CN101095698B (zh) * 2006-06-26 2010-12-01 青岛东海药业有限公司 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途
ITMI20071214A1 (it) 2007-06-15 2008-12-16 S I I T Srl Servizio Internazi Composizioni a base di componenti prebiotici ed immunogenici per la prevenzione e il trattamento di disturbi gastroenterici da disbiosi e/o alterazioni della normale flora intestinale
CN101998859B (zh) * 2008-03-18 2014-03-05 亚历山大·弗拉基米罗维奇·季科夫斯基 用于预防与抗生素肠道给药相关的生态失调的药物组合物
EP2110028A1 (en) * 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
GB0809921D0 (en) 2008-05-30 2008-07-09 Clasado Inc Product and process therefor
US8425930B2 (en) 2009-03-13 2013-04-23 The Regents Of The University Of California Prebiotic oligosaccharides
MX2012005015A (es) * 2009-10-30 2012-06-12 Prometheus Lab Inc Metodos para diagnosticar sindrome de intestino irritable.
RU2012123959A (ru) * 2009-11-12 2013-12-20 Нестек С.А. Питательная композиция, способствующая балансу микробиоты и оказывающая благоприятное воздействие на состояние здоровья
US20120276208A1 (en) 2011-04-27 2012-11-01 University Of South Australia Acute cognitive and mood effects of plant polysaccharides in adult human subjects

Also Published As

Publication number Publication date
WO2014155056A1 (en) 2014-10-02
GB2515865B (en) 2017-05-10
US11241449B2 (en) 2022-02-08
SG11201507668UA (en) 2015-10-29
GB201305708D0 (en) 2013-05-15
CN105073120A (zh) 2015-11-18
GB2515865A (en) 2015-01-07
HK1204451A1 (en) 2015-11-20
CA2908230C (en) 2021-04-13
US20160045524A1 (en) 2016-02-18
CA2908230A1 (en) 2014-10-02
US20220143054A1 (en) 2022-05-12
ES2722852T3 (es) 2019-08-19
IL241844B (en) 2018-06-28
MX2015013699A (es) 2016-05-31
AU2014242798B2 (en) 2018-07-05
AU2014242798A1 (en) 2015-10-08
TWI507198B (zh) 2015-11-11
SG10201707152TA (en) 2017-10-30
JP2016516743A (ja) 2016-06-09
MY175533A (en) 2020-07-01
RU2663696C2 (ru) 2018-08-08
TW201444562A (zh) 2014-12-01
GB201405503D0 (en) 2014-05-14
EP2978432A1 (en) 2016-02-03
KR102235730B1 (ko) 2021-04-02
EP2978432B1 (en) 2019-02-20
AR095738A1 (es) 2015-11-04
JP6309612B2 (ja) 2018-04-11
KR20150135504A (ko) 2015-12-02
KR20210038701A (ko) 2021-04-07
RU2015146305A (ru) 2017-05-04

Similar Documents

Publication Publication Date Title
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
BR112016018408A2 (pt) moléculas de anticorpo à lag-3 e usos das mesmas
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112017007379A2 (pt) moléculas de anticorpo para pd-l1 e usos das mesmas
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
BR112015024625A2 (pt) composição de galacto-oligossacarídeo para o uso na prevenção ou tratamento de disfunção cognitiva e transtornos emocionais em doenças neuropsiquiátricas ou envelhecimento
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112014018471A2 (pt) anticorpos anti-ige m1' e métodos para o seu uso
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
CL2014003339A1 (es) Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
CL2016001578A1 (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c.
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements